President & CEO: Samuel F. Straface, Ph.D.
Dr. Straface joined Medrobotics in March, 2009 after serving as an Executive-in-Residence at The Pittsburgh Life Sciences Greenhouse, an incubator in Pittsburgh Pennsylvania, where he led a portfolio of life science companies with business formation, development and financing. Previously, he was the founding President and Chief Executive Officer of Triton BioSystems, Inc. (now Aduro BioTech, Inc.), a targeted nanobiotechnology company developing low side-effect highly selective therapies for advanced cancers such as head and neck, breast and prostate cancers. Dr. Straface has over 30 years of experience in global sales, marketing, business development, venture financing and general management at several companies, including Boston Scientific Corporation, and Johnson & Johnson. He began his career as a Scientific Officer, researching the neurophysiology of the retina and methods for early diagnosis of neuronal disease. He holds a Ph.D. in neurophysiology from the University of Western Australia.
Chief Financial Officer and Treasurer: Mark A. Peters, CPA
Mark Peters has 26 years of financial leadership, operations management, and strategic planning experience in private and public companies, including successful IPO experience. Mr. Peters began his career with PricewaterhouseCoopers then IBM before focusing on emerging medical technology companies. His experience includes Chief Financial Officer/Vice President roles for Seikagaku America, a global manufacturer of endotoxin detection re-agents; IST, a venture backed spinal implant company; and Health Language, a private equity backed healthcare IT company. Mr. Peters also led operations as General Manager for Aura Medsystems, a tissue closure company founded on technology from Harvard Medical School/Mass. General Hospital. Mr. Peters is a licensed CPA, earned a BBA in Accounting from The University of Texas and an MBA in Finance from The University of Notre Dame, where he currently serves on the Board of Directors for the graduate business school. He previously served on the Board of Directors for MassMEDIC (Massachusetts Medical Device Industry Council).
Vice President, New Business Development:
Russell M. Singleton, Ph.D.
Dr. Singleton joined Medrobotics in April, 2013 after consulting for several complex imaging and automation equipment companies in the medical device and life science sectors. His extensive corporate experience spans roles including VP R&D, CEO, COO and general management. Dr. Singleton has led complex technology organizations through significant inflection points and growth including a successful turnaround of a division of Philips Healthcare. As VP R&D of Molecular Dynamics, his team drove the growth of the company through a successful IPO and eventual acquisition by GE Healthcare. His systems, vision and automation expertise was honed from eighteen years at KLA-Tencor, a dominant semiconductor inspection and measurement company. Dr. Singleton received his B.E. (Electrical) from Pratt Institute, and his M.S. and Ph.D. from the University of Illinois in Electrical Engineering. He completed the AEA/Stanford University Executive Institute program on ‘Management of High Tech Companies.’
Vice President Operations: Michael W. Gallagher
Mr. Gallagher has over 27 years of experience in manufacturing operations and engineering management. He began his career in the medical device industry at Aspect Medical Systems, the market leader in depth of consciousness monitoring technology. He held increasingly more responsible management positions at Aspect and when Covidien acquired Aspect in 2009, he became Plant Engineering Manager for the Company’s main facility. He was responsible for supply chain development, manufacturing engineering, product sustaining engineering, and manufacturing operations transfers both domestic and international. Earlier in his career he held engineering management and equipment design engineering positions at Reflection Technology, Bose and Raytheon. Mr. Gallagher holds both a BS and MS in Electrical Engineering from the University of Massachusetts-Lowell.
Vice President, Global Sales: Richard S. Walsh
Mr. Walsh brings over 20 years of medical device sales and sales management experience with a focus mainly on emerging growth medical device technologies. Most recently, Mr. Walsh was Vice President of Sales for NeoTract, Inc., a company which develops and commercializes surgical products for the urology market. Previously, he was the Director of Global Sales and Integration at Acclarent, a pioneer in the development and commercialization of products for the ENT market, where he was responsible for the integration of the Acclarent international distribution network into the Johnson & Johnson Ethicon commercial organization. Prior to that, he was Eastern Area Director of Sales at Acclarent where he grew the Eastern U.S. balloon sinuplasty business to $34 million and was elected Sales Director of the Year for 3 consecutive years. Before Acclarent, Mr. Walsh held the Vice President of Sales position at Atricure (NASDAQ: ATRC) and Stereotaxis (NASDAQ: STXS). Before Stereotaxis, he was Sales Director, Eastern United States, at Intuitive Surgical (NASDAQ: ISRG) where he helped commercialize the DaVinci Surgical Robot. Mr. Walsh began his medical device sales management career at United States Surgical (now Covidien) where he was Regional Sales Manager, Mid-Atlantic Region. Mr. Walsh received a Bachelor of Science degree in Professional Aviation Studies from Embry Riddle and served for 7 years in the U.S. Army as an Army Aviation Officer.
Vice President, Clinical, Regulatory & Quality Affairs:
John D. Bonasera
Mr. Bonasera brings over 30 years of experience in the medical device industry, having directed quality assurance, regulatory affairs and clinical development at multinational corporations and early stage medical technology companies. He has been responsible for developing and executing effective and novel strategies to navigate challenging regulatory paths to achieve FDA and foreign approvals that led to the commercialization and/or clinical trials of a variety of complex medical devices including implanted drug delivery systems, implanted resorbable spinal implants, and embolic micro particles. Prior to joining Medrobotics he directed clinical trials of new and innovative technologies including the use of a patient’s own stem cells to create new blood vessels in untreatable vascular disease to prevent amputation of the leg and foot and to improve cardiac function after heart failure. In each regulatory and clinical project he lead teams of engineers, physicians, attorneys, statisticians and other experts. Mr. Bonasera has a BA in Biology and Psychology from the University of Massachusetts. He is a certified regulatory professional and a certified medical technologist. In his early career he supervised hospital laboratories and received a faculty appointment to Northeastern University to teach clinical laboratory science.
Vice President, Intellectual Property Strategy:
J. Christopher Flaherty
Mr. Flaherty has more than 25 years as a technologist and prolific inventor. He was formerly the Executive Vice President, Technology and Intellectual Property of Cyberkinetics Neurotechnology Systems, Inc. Mr. Flaherty founded Insulet Corporation in July 2000 and served as its President and Chief Operating Officer until January 2002. Mr. Flaherty also co-founded TransVascular, Inc. in March 1996 and served as its Executive Vice President until June 2003. Mr. Flaherty has held positions at Pfizer (NYSE:PFE) and Strato Medical. Mr. Flaherty earned a B.S. in Aeronautical and Electrical Engineering from Massachusetts Institute of Technology in 1985.